A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal Transplantation
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase II/III, randomized, open-label, active-controlled, multicenter trial to
evaluate the safety and efficacy of efalizumab compared with cyclosporine (CsA), when both
are given in combination with Mycophenolate Mofetil (MMF) and corticosteroids after induction
therapy with basiliximab, as an immunosuppressant regimen in de novo renal transplantation. A
total of 200 subjects undergoing either living or cadaveric renal transplantation will be
randomly assigned 1:1 to receive either efalizumab + MMF + corticosteroids or CsA + MMF +
corticosteroids.